Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2023 Earnings Call Transcript August 1, 2023
Esperion Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.05 EPS, expectations were $-0.61.
Alexis: Sheldon Koenig – President and Chief Executive Officer Eric Warren – Chief Commercial Officer Benjamin Halladay – Chief Financial Officer JoAnne Foody – Chief Medical Officer Betty Swartz – Chief Strategy Officer
Operator: Ladies and gentlemen, thank you for standing by and welcome....
